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A B S T R A C T 
Introduction: Genetic risk factors and family history 
play an important role in breast cancer development. 
This review aimed to summarise the current genetic 
testing approach to hereditary breast/ovarian cancer.
Methods: A systematic literature review was 
performed by searching the PubMed database. 
Publications available online until January 2015 that 
addressed issues related to hereditary breast/ovarian 
cancer genetic counselling/testing were selected. 
The search terms used were “familial breast/ovarian 
cancer”, “susceptibility genes”, “genetic counselling”, 
and “genetic testing”. The data extracted for this 
review were analysed by the authors, with a focus on 
genetic testing for hereditary breast/ovarian cancer. 
Results: Although a greater proportion of inherited 
breast/ovarian cancers are due to the BRCA1 and 
BRCA2 mutations, a number of new genes have 
emerged as susceptibility candidates, including rare 
germline mutations in high penetrance genes, such 
as TP53 and PTEN, and more frequent mutations 
in moderate/low penetrance genes, such as PALB2, 
CHEK2 and ATM. Multi-gene testing, if used 
appropriately, is generally a more cost- and time-
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Introduction
Breast cancer is one of the most common cancers 
and the second most common leading cause of 
cancer-related death among women with 1.67 
million new cases diagnosed in 2012 (25% of all 
cancers).1 About 39% of these new cases are found in 
Asia.1 In the US, women have a 12% lifetime risk of 
developing breast cancer including women of young 
age. In addition, approximately 1 in 250 women in 
their 30s will develop breast cancer in the next 10 
years.2 Assessment of an individual’s risk for breast 
cancer is complex, and based on different aspects 
such as personal lifestyle, environmental exposure, 
reproductive influences, and drug use. Genetic 
risk factors and family history, however, also play 
important roles in breast cancer development. Only 
5% to 10% of breast cancer cases are characterised 
as hereditary and follow the autosomal dominant 
pattern of transmission.3 On the other hand, 15% 
to 20% of breast cancer cases are familial, referring 
to women who have two or more first- or second-
degree relatives with the disease.4-6 Hereditary 
cancers follow a Mendelian inheritance pattern and 
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tend to have an earlier age of onset. Familial cancers 
do not follow a specific inheritance pattern. Defects 
in the BRCA1 and BRCA2 genes are the most well-
known high-risk factors among inherited breast 
cancers. Results from genome-wide association 
studies have broadened our knowledge over the last 
few years about the specific genes that contribute to 
familial breast cancer. Other genes such as TP53 and 
PTEN have also been identified to be associated with 
an increased risk of breast cancer.7 High-risk women 
are likely to benefit from genetic testing as there are 
now emerging targeted therapies and interventions 
that have been shown to improve outcome in 
mutation carriers.
Methods
A search of the medical literature was performed to 
identify the relevant studies and reviews on genetic 
testing for hereditary breast/ovarian cancer. The 
PubMed database was searched for publications 
available online until January 2015 that address 
the related issues; “familial breast/ovarian cancer”, 
“susceptibility genes”, “genetic counselling”, and 
REVIEW ARTICLECME
effective method than single-gene testing, and may 
increase the number of patients who can be offered 
personal surveillance, risk-reduction options, and 
testing of high-risk family members. 
Conclusions: Recent advances in molecular genetics 
testing have identified a number of susceptibility 
genes related to hereditary breast and/or ovarian 
cancers other than BRCA1 and BRCA2. The 
introduction of multi-gene testing for hereditary 
cancer has revolutionised the clinical management 
of high-risk patients and their families. Individuals 
with hereditary breast/ovarian cancer will benefit 
from genetic counselling/testing.
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遺傳性乳腺癌/卵巢癌的新一代基因檢測
鄺靄慧、陳嘉偉、冼念慈
引言：遺傳風險因素和家族史是乳癌發病的關鍵因素。本文概括目前
針對遺傳性乳腺癌/卵巢癌的基因檢測方法。
方法：通過PubMed數據庫搜索直至2015年1月為止所有有關遺傳
性乳腺癌/卵巢癌和基因諮詢/檢測的文章。用以搜索文獻的關鍵詞 
為「家族性乳腺癌/卵巢癌」（familial breast/ovarian cancer）、
「易感基因」（susceptibility genes）、「遺傳諮詢」（genetic 
counselling）和「基因檢測」（genetic testing）。針對遺傳性乳腺
癌/卵巢癌的基因檢測，筆者把搜索到的文章作重點分析。
結果：縱使大多數遺傳性乳腺癌/卵巢癌均由BRCA1和BRCA2基因突
變引起，另一些新的易感基因也逐漸被認為是這種癌症的關聯基因，
包括具有高外顯率如TP53和PTEN的罕見突變基因，以及具有中/低
外顯率如PALB2、CHEK2和ATM的常見突變基因。一般來說，如使
用得當，多基因檢測組合較單基因檢測省時及更具成本效益，令更多
基因檢測呈陽性的患者得到個人監測、更多降低風險的選擇，以及替
高風險的家族成員作檢測。
結論：分子遺傳學測試的最新發展讓我們確定除了BRCA1和BRCA2
基因突變，還有其他引致遺傳性乳腺癌/卵巢癌的易感基因。引入多基
因檢測組合對於高風險患者和其家族成員的臨床管理來說起了革命性
的作用。遺傳性乳腺癌/卵巢癌患者將受惠於遺傳諮詢/檢測。
“genetic testing” were used as the search terms.
High-penetrance genes
BRCA1 and BRCA2
Hereditary breast and ovarian cancer syndrome 
(HBOC) refers to a germline mutation in either the 
BRCA1 or BRCA2 gene, and individuals who carry 
a mutation have an increased risk of developing 
cancers. BRCA1 and BRCA2 are tumour-suppressor 
genes that code for proteins that help repair damaged 
DNA and therefore play vital roles in securing the 
stability of the cell’s genetic material. Defects in these 
two genes may result in protein with malfunction, 
thus DNA damage may not be repaired properly. As 
a result, cells are prone to develop genetic mutations 
leading to cancer development. Scientists discovered 
in the 1990s that BRCA1 and BRCA2 are breast 
cancer susceptibility genes.8,9 Women have a 57% to 
60% and 49% to 55% lifetime risk of developing breast 
cancer if they carry a BRCA1 or BRCA2 mutation, 
respectively.10,11 Women with mutations in the 
BRCA1 cancer susceptibility gene associated with 
HBOC have a 39% to 46% risk of developing ovarian 
cancer by the age of 70 years while approximately 
10% to 27% BRCA2-positive women are at risk.12-14 
The result of genetic testing for the BRCA mutation 
is important to decisions made about management 
of breast cancer. For example, a woman diagnosed 
with breast cancer and who harbours the BRCA1 
or BRCA2 mutation has a greater risk of developing 
a second breast cancer in the contralateral breast, 
and this risk is age-related. Women diagnosed with 
breast cancer at a younger age have a higher risk of 
developing contralateral malignancy compared with 
those diagnosed at an older age.15 BRCA1 mutation 
carriers tend to have more triple-negative breast 
cancer (TNBC), medullary histopathology, somatic 
TP53 mutations, higher histological grade, and 
present at a younger age compared with women 
with sporadic breast cancers. Basal markers such as 
cytokeratin (CK14, CK5/6, CK17), osteonectin, and 
EGFR are more commonly expressed in BRCA1-
positive tumours than in control tumours unselected 
for mutation status.16-18 The National Comprehensive 
Cancer Network (NCCN) annually updates 
guidelines with respect to genetic counselling and 
testing (www.nccn.org) and the most updated 
guidelines recommend it for individuals who meet 
the HBOC testing criteria. Guidelines are based on 
young age of onset, family history of breast cancer, 
specific histological types of breast cancer (TNBC), 
ovarian (epithelial and peritoneal), and prostate 
cancer (Gleason score ≥7). For details refer to NCCN 
guidelines (Genetic/Familial High-Risk Assessment: 
Breast and Ovarian), version 1.2016.19 
 Knowing the mutation status of germline BRCA1 
and BRCA2, patients may be offered alternative 
screening and/or therapeutic interventions 
(Table 119), including intensive breast surveillance 
(magnetic resonance imaging [MRI] of the breasts 
in addition to standard breast imaging such as 
mammography and ultrasonography), mastectomy 
instead of breast conservation surgery, prophylactic 
mastectomy and salpingo-opherectomy, or the 
prescription of chemopreventive drugs and more 
recently the choice of chemotherapy as primary 
treatment, for example, carboplatin. A recent study 
has shown that treatment with carboplatin produces 
no advantage over docetaxel in patients with TNBC, 
although those with BRCA1 or BRCA2 mutation 
benefited from either drug.20 A number of targeted 
therapies, such as poly(ADP-ribose) polymerase 
inhibitors, have been shown to be effective in BRCA 
mutation carriers.21,22 The evolution of sequencing 
technologies enables parallel testing of multiple 
genes, leading to simultaneous analysis of breast 
cancer predisposition genes with either high or 
intermediate penetration. Multi-gene panel testing, 
however, has raised new issues regarding patient 
eligibility for gene testing other than BRCA1 and 
BRCA2, and more importantly, interpretation of 
genetic results.
TP53
One of the high penetrance genes is TP53, which 
is a tumour-suppressor gene that encodes the 
transcription factor protein p53. It is a ubiquitous 
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protein implicated in preservation of an intact 
genome. It regulates cell cycle, DNA repair, apoptosis, 
cellular senescence, and metabolism. It has been 
shown to be involved in various kinds of cancer 
progression such as osteosarcomas, colon cancer, 
and lung cancer.23-28 Li-Fraumeni syndrome (LFS) is a 
rare but highly penetrance familial cancer syndrome 
that is characterised by germline TP53 mutations 
inherited in an autosomal dominant manner, in which 
60% to 80% of LFS families carry a mutant TP53.29 In 
addition to soft-tissue sarcomas and osteosarcomas, 
LFS families are likely to exhibit a pattern of early-
onset and multiple primary cancers including 
breast, brain, and adrenocortical tumours29,30; LFS 
is thought to account for approximately 1% of all 
breast cancers.31,32 Approximately 1% of women 
diagnosed with breast cancer before the age of 
40 years carry a TP53 mutation.32 Breast cancer 
is the most frequent malignancy among female 
TP53 mutation carriers and accounts for up to 
one third of all cancers in LFS families.33 Although 
LFS is only responsible for a tiny fraction of breast 
cancers, women with LFS have a breast cancer 
risk of 56% by the age of 45 years and greater than 
90% by the age of 60 years, and LFS accounts for a 
60-fold increased risk for early-onset breast cancer 
compared with the general population.34,35 Women 
with LFS-related breast cancer are reported to 
have very early disease onset (20s or 30s) and a 
relatively advanced disease staging.36-38 Studies have 
shown that 3% to 8% of women who are diagnosed 
with breast cancer younger than 30 years without 
a significant family history of cancer have TP53 
mutation.31,39,40 The NCCN has included early-onset 
breast cancer as one of the criteria for offering TP53 
genetic testing, regardless of the family history 
of cancer. TP53 mutations can be tested either 
through sequencing the entire encoding region that 
identifies approximately 95% of TP53 mutations or 
just selected regions. Analysis of hot-spot regions 
located in exons 4-9 can detect approximately 90% of 
all TP53 mutations.19,41,42 When the TP53 mutation 
is present in an individual, breast screening and 
preventive guidelines are similar to those for BRCA 
mutation carriers. In addition, a full-body MRI scan 
is an option as a screening tool. Individuals with 
the following should be included for genetic testing 
of TP5319: early-onset breast cancer (≤35 years), a 
combination of diagnosis of a sarcoma at the age of 
<45 years, AND a first-degree relative diagnosed at 
the age of <45 years with cancer, multiple cancers 
(brain tumours, sarcomas, and leukaemia).
PTEN
PTEN is a phosphatase tensin homologue located 
on chromosome 10q23.3 that plays a tumour-
suppressive role due to its PI3K (phosphatidylinositol-
3-kinase) phosphatase activity. Abnormal PTEN 
cannot activate cell cycle arrest and apoptosis and 
leads to uncontrolled cell survival.43 Germline 
PTEN mutations have been identified in a variety 
of disorders such as Cowden syndrome (CS) or 
PTEN hamartoma tumour syndrome. Affected 
individuals have multiple hamartomas in a variety 
of tissues with an increased risk of malignant 
transformation.44 Breast cancer is the most 
common tumour associated with CS. Although 
CS is responsible for <1% of all breast cancers, 
women with this syndrome have a 25% to 50% risk 
of developing breast cancer in a lifetime and are 
prone to early onset.45,46 The frequency of multifocal 
and bilateral disease is increased in CS-associated 
breast cancers compared with sporadic cases.47,48 
TABLE 1.  NCCN management of the hereditary breast and/or ovarian cancer syndrome19
(Adapted from the NCCN guidelines, version 1.2016)
Management of hereditary breast and/or 
ovarian cancer syndrome
Details
Breast screening Annual breast MRI screening or mammogram for age 25-29 years. Breast MRI screening and 
mammogram for age ≥35-70 years. Individual consideration for age >70 years
Risk-reducing mastectomy Counselling may include a discussion regarding degree of protection, reconstruction options, and 
risks
Risk-reducing salpingo-oophorectomy is 
recommended for those aged 35-40 years 
and upon completion of child bearing
Counselling may include a discussion of reproductive wishes, extent of cancer risk, degree of 
protection for breast and ovarian cancer, and management of menopausal symptoms
Address the psychosocial, social, and  
quality-of-life aspects
For those who have not selected risk-reducing salpingo-oophorectomy, consider concurrent 
transvaginal ultrasound and CA-125 monitoring starting at 30 years or 5-10 years before the 
earliest age of first diagnosis of ovarian cancer in the family
Consider chemoprevention for breast cancer 
and ovarian cancer
-
Consider investigational imaging and 
screening studies 
-
Abbreviations: MRI = magnetic resonance imaging; NCCN = National Comprehensive Cancer Network
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Women with CS also have an increased risk (67%) 
of benign breast disease characterised by mammary 
hamartomas that can be multiple and bilateral.49 
Similar to TP53 mutation carriers, PTEN mutation 
carriers are advised to have breast surveillance and 
interventions as recommended for BRCA mutation 
carriers. The testing criteria for CS are those who 
present with breast cancer, endometrial cancer, 
follicular thyroid cancer, multiple gastrointestinal 
hamartomas, ganglioneuromas, or other diseases 
including macrocephaly, macular pigmentation of 
glans penis, and mucocutaneous lesions.19 
Moderate- and low-penetrance 
genes
PALB2
PALB2 (partner and localiser of BRCA2) is involved 
in homologous recombination and double-strand 
break repair along with BRCA2.50,51 Loss-of-function 
mutations are associated with a 2 to 4 times higher 
risk than non-mutation carriers for familial breast 
cancer.52-54 A study analysed the risk of breast 
cancer among 362 members of 154 families who 
had deleterious PALB2 mutations.55 The results 
revealed that the risk of having breast cancer for 
female PALB2 mutation carriers was 8 to 9 times 
higher among those younger than 40 years, 6 to 8 
times higher among those 40 to 60 years, and 5 times 
higher among those >60 years when compared with 
the general population. The estimated cumulative 
risk of breast cancer among female mutation carriers 
increased from 14% to 35% from the age of 50 to 70 
years. In addition, the risk of breast cancer for PALB2 
mutation carriers was significantly increased by 
familial factor.56 Thus, it has been advised that PALB2 
mutation testing should be performed routinely to 
identify mutations in HBOC families since it may 
be of clinical relevance. This is increasingly being 
tested.
Other hereditary breast cancer 
susceptibility genes
There are other low-penetrance genes that are 
associated with hereditary breast cancer such 
as STK11, CDH1, and MMR genes, and that 
are responsible for Peutz-Jeghers syndrome, 
hereditary diffuse gastric cancer syndrome, and 
Lynch syndrome, respectively.57-59 Some moderate-
penetrance genes such as CHEK2, ATM, BRIP1, 
RAD51C, RAD51D, BARD1, MRE11, RAD50, NBS1, 
and FANCM have been recognised as breast cancer 
susceptibility genes.60
 The recent development of multi-gene testing 
for hereditary cancer has had a great impact on the 
clinical management and genetic counselling of 
high-risk patients and their families. The decision 
to use multi-gene testing should be no different 
than the rationale for testing a single gene. Multi-
gene testing is more cost-effective than sequentially 
testing multiple genes associated with a phenotype. 
For example, young women diagnosed with breast 
cancer can be tested for mutations in BRCA1, 
BRCA2, and TP53. Detailed testing criteria for genes 
can be found in NCCN guidelines version 1.2016.19 
Next-generation sequencing enables simultaneous 
analysis of a specific panel of genes, but there are 
limited outcome data on clinical interventions, 
particularly in lower-penetrance-gene-mutation–
related breast cancers. Results of a multi-gene panel 
may pose difficulty in interpretation and clinical 
decisions. At present, multi-gene testing is largely 
performed for research purposes. There are limited 
data regarding the degree of cancer risk associated 
with some of the genes on the recurrent multi-gene 
test. There is a lack of well-established guidelines for 
risk management for carriers of mutations in some 
of the genes, which may lead to extra surveillance 
and surgeries. 
 Nonetheless multi-gene testing is more cost-
effective and time-effective than single-gene testing, 
and provides a higher mutation detection rate. It 
may reduce the number of high-risk families with 
negative results of finding a gene mutation due to the 
increased coverage. The lifetime breast cancer risk 
estimates associated with gene mutations are listed 
in Table 2.10,13,36,56,58,61-74
 In Hong Kong, breast cancer is the most 
common cancer in the female population. The Hong 
Kong Hereditary Breast Cancer Family Registry 
was established in 2007. It functions as a data 
registry of hereditary breast, ovarian and prostate 
cancer families and is also an established charitable 
organisation that subsidises the cost of genetic 
testing for underprivileged individuals. More than 
1900 patients with breast and/or ovarian cancer 
who satisfied the selection criteria have received 
genetic testing in Hong Kong. Each individual 
underwent thorough genetic counselling to ensure 
the implications of genetic testing were understood. 
TABLE 2.  Estimated lifetime risk of breast cancer associated 
with selected susceptibility genes10,13,36,56,58,61-74
Gene Estimated lifetime risk of breast cancer
BRCA1 55-65%10
BRCA2 45-47%13
TP53 49-60%36
PTEN 25-50%61,62
PALB2 33-58%56
STK11 30-50%58,63,64
CDH1 39-52%65,66
ATM 15-52%67-70
CHEK2 20-44%71-74
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Around 600 probands were screened for BRCA1 
and BRCA2 mutations by bi-directional Sanger 
sequencing of all coding exons and multiplex ligation-
dependent probe amplification.75 The sensitivity of 
identifying mutations is comparable with the gold-
standard method with good bioinformatics support. 
Next-generation sequencing meets rigorous quality 
standards and can provide clinical sequencing results 
that are equivalent to those obtained from Sanger 
DNA sequencing analysis.76 We started employing 
next-generation DNA sequencing to expedite 
analysis workflow and expand the gene panel in 
2011 to include TP53 and PTEN for sequencing. 
Cases with a negative result after screening with 
our in-house developed gene panel are further 
sequenced using 454 GS Junior System (Roche Life 
Sciences) or MiSeq (Illumina). Sequencing data are 
analysed by an in-house fully developed automatic 
bioinformatics pipeline. The mutation screening 
result of a 4-gene panel BRCA1, BRCA2, TP53, and 
PTEN in our recruited patients revealed that 9% 
carried such mutations. Nonetheless a number of 
clinically high-risk patients have tested negative for 
the above genes. This indicates that there is further 
potential in expanding the coverage to different 
lower-penetrance genes such as PALB2, which has 
recently been reported to be important to cause 
hereditary breast cancer in our testing strategy.56
Conclusions
Clinical assessment of an individual’s risk of 
hereditary cancer is based on the evaluation of family 
history, age of onset, and type of cancer. Advances in 
molecular genetics testing have identified a number 
of genes associated with inherited susceptibility 
to breast and/or ovarian cancers such as BRCA1, 
BRCA2, PTEN, and TP53. The recent introduction 
of next-generation sequencing technology and 
multi-gene panel testing for hereditary cancer has 
rapidly altered the clinical approach to high-risk 
patients and their families. Although there are still 
limitations, individuals with hereditary or familial 
breast/ovarian cancer are likely to benefit from 
strategies including prevention, screening, and 
targeted treatment. Suitable patients and families 
should be offered genetic counselling and testing.
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